We last investigated whether NSCLCs with a PD-L1 TPS of greater than or equal to 90% had distinct immunophenotypic correlates compared with those with a PD-L1 TPS of 50% to 89% and performed mIF for CD8, PD-1, Foxp3, PD-L1, and AE1/AE3 (Cytokeratin) on tumor tissue from 69 NSCLCs with PD-L1 TPS of 50% to 89% and 24 NSCLCs with PD-L1 TPS greater than or equal to 90%. The gene discussed is PDCD1; the disease is neoplasm.